The new name for Medical Solutions is officially Source BioScience - a really catchy name!
Read the last postings under [MLS] and you'll see it was way-back in 2007.

Oh dear, Zzzz.

Er, anyone still there?
. . . . . This new Business is slightly different, having bought another company recently - but then failing companies always think they can "trade" out of problems. . . . .
The problem?

For me it's the regular holding of investor-meetings in Nottingham ( M1- half-way, turn right...keep your speed down; this county uses cameras for pension funding.).

Anyone living near Nottingham - and going to the AGM - can you tell us how things are.....did they show any product?
//
No? - well, no change then.

A bit of life in one of my tech boom dogs.

Source BioScience to provide companion diagnostic testing service for stomach cancer

Source BioScience plc (LSE: SBS), the provider of expert, quality services to the life science research, pharma biotech and healthcare sectors, is pleased to announce that the Company will provide a companion diagnostic testing service for stomach cancer patients in the UK.

Source BioScience is the first reference centre in the UK to provide validated HER2 status testing as a companion diagnostic for possible Herceptin (trastuzumab) therapy for stomach cancer patients.

Up 17% today - I guess it may be the SUN effect.

I am removing ALL my research from here due to the constant personal abuse, defamation and distortions of it posted by:

ptholden

hlyeo98

halifax

blackdown

kimoldfield

cynic


This bunch of abusive retards is the reason MoneyAM will NEVER have a forum worth reading.

I have reported them to support by they do nothing, either because they want to force me to PAY them for the Traders Room or because they are too lazy to do anything. Maybe the people in support are the ones perpetrating the abuse, so as to force people to pay for the premium boards. Either way the service is sh1te and a disgrace to the finance industry. No wonder there is nobody left here apart from morons.

I will continue posting my good research on boards that are run in accordance with FSA and LSE listing rules and the interests of the market, not here where ar5eh0les rule the boards and all decent research is buried under their piles of sh1te.

Interim Management Statement.

Highlights:

* Revenue increased 19% year on year underpinned by strong growth in
diagnostics and life sciences; overall performance in line with
expectations for the year to date

* Installation of second Illumina HiSeq 2000 next generation sequencing
platform in the new Berlin facility

* New DNA sequencing service launched from the recently acquired facility in
Berlin

* European Union Framework 7 grant awarded to imaGenes to study genetic
causes of dementia in children; worth in excess of GBP200k

* SpeedREAD rapid data delivery service for DNA sequencing launched,
providing the world's fastest turn around for sequencing data in under 3
hours

* Approval for direct connection to NHS internal IT network; competitive
advantage by removing a barrier to outsourcing work

* Strong financial position with GBP3.3 million of cash at the end of March
2011 (31 December 2010: GBP4.2 million) to underpin investment and
acquisition plans

23 August 2011

Source BioScience plc

("Source BioScience" or "the Company" or "the Group")

HALF YEARLY REPORT FOR THE SIX MONTHS ENDED 30 JUNE 2011

The Board of Source BioScience plc (LSE: SBS) the international genetic
analysis and diagnostics business, presents its half yearly report for the six
months ended 30 June 2011.

Financial highlights

* Revenue increased by 10% to GBP7.6 million (2010: GBP6.9 million), with a major
contribution from LifeSciences which showed a 31% increase in revenue in
the period

* Loss before tax of GBP0.2 million (2010: GBP0.1 million profit) after GBP0.4
million of non-recurring and restructuring costs associated with the
planned integration of the acquired imaGenes business

* EBITDA of GBP0.5 million (2010: GBP0.6 million)

* Annualised cost savings of approximately GBP0.5 million identified and will
benefit the Group during H2 2011

* Cash balance of GBP3.0 million (31 December 2010: GBP4.2 million)

Operational highlights

* Major developments in LifeSciences business driving growth:

+ Launch of the world's largest clone and antibody portfolio, combining
over 20 million clones and integrated antibody library

+ Release of GenomeCube, a proprietary search engine and bioinformatics
tool enabling researchers to access the entire portfolio quickly and
easily

+ SpeedREAD rapid data delivery service for DNA sequencing launched,
providing the world's fastest turnaround times for sequencing data of
less than three hours; also, leading Overnight Service launched

+ Installation and commissioning of the Company's second HiSeq2000 high
throughput sequencing platform in the Berlin facility to meet
increasing customer demand for genetic sequencing services

* New competitive advantage created for the Healthcare outsourcing business
through direct connection to the NHS' internal IT network

* Awarded European Union Framework 7 grant to study genetic causes of
dementia in children, worth in excess of GBP0.2 million

Post period events

* Important revenue growth opportunity for Healthcare with NHS approval for
the use of the BD FocalPoint "No Further Review" technology for cervical
cancer screening in the UK with potential sales increase by up to 25% in
the long term

* Won prestigious international competitive bid to provide DNA sequencing to
Trinity College Dublin and University College Dublin - expected to generate
revenue of at least GBP0.3 million per annum

Laurie Turnbull, Chairman of Source BioScience, said:

"In this period, we have seen significant growth in our LifeSciences business,
boosted by the integration of the imaGenes acquisition and the growing demand
for sequencing and genomic services in the life sciences research sector. This
division will continue to be the major driver of growth for the business. We
are also seeing longer term growth opportunities in the Healthcare division
which has always been a solid performer. We have a significant competitive
advantage following our approval to link in to the NHS hospitals IT network and
from the approval of our BD FocalPoint "No Further Review" technology. This
technology represents a major breakthrough in automation of cervical cancer
screening and we are the sole provider. As a leader in the provision of genetic
and diagnostic services, the business is cost-efficient, restructured and
well-positioned to meet the growing demands of the European healthcare and life
sciences sectors."

---ENDS---

Interim Management Statement.

INTERIM MANAGEMENT STATEMENT

Source BioScience achieves double digit Q3 revenue growth (year on year); full
year profits expected to be in line with market expectations

Source BioScience plc (LSE: SBS), the international diagnostics and genetic
analysis business serving the healthcare and research markets today provides
its Interim Management Statement as required by the UK Listing Authority's
Disclosure and Transparency Rules, relating to the period from 1 July 2011 to
15 November 2011.

Unless otherwise stated, the financial information referenced below refers to
the three months ended 30 September 2011, and the corresponding period last
year, this being the latest practicable date to which financial information has
been prepared.

Overall business performance

The third quarter of 2011 has been another period of growth and development for
Source BioScience. Revenue is up 17% compared with the same period last year
and 13% over the full nine months. This performance has been underpinned by
strong growth in the LifeSciences division and Healthcare's cervical cancer
screening business.

In the first half of the year, the Company undertook a cost cutting exercise in
connection with the acquisition and integration of imaGenes, which is
continuing to have a beneficial effect on the business in the second half of
the year. We are also in a strong financial position with 3.1 million of cash
at the end of September 2011 (30 June 2010: 3.0 million).

Overall performance for the year to date is in line with management's
expectations, representing a continuation of the strong growth and business
performance achieved last year. We continue to expect full year profits to be
in line with market expectations.

LifeSciences division

This division's revenue was up 54% year on year based on strong growth in DNA
sequencing and life science products and over the nine month period it was up
37%. Much of the increase in sales was due to the launch of an enhanced website
for customers and the GenomeCube platform, our proprietary search engine and
bioinformatics tool. Website traffic was up by more than 50% and internet
orders up more than 20% compared with the same period last year. In addition,
the Overnight Service for DNA sequencing was launched in Berlin and Oxford
during the period. Finally, we won an international bid to provide DNA
sequencing to Trinity College Dublin and University College Dublin which is
worth an expected minimum 300,000 per year.

Healthcare division

Demand for our liquid based cytology (`LBC') service, which underpins 48% of
the cervical cancer screening programme in England and Wales, was strong during
the period. An additional important milestone was receiving approval from the
NHS for the BD FocalPoint automated cervical cancer screening technology which
is an important revenue growth opportunity for us. In diagnostics, as
anticipated, we are seeing a shift in demand towards gene-based diagnostic
testing and 30% now has a genetic component compared with 20% in the same
period last year. We believe this is indicative of the future of this business
and we see strong growth and development opportunities in this specialist area.

-- ENDS --

Source BioScience plc

("Source BioScience" or the "Company")

NHS publishes Implementation Guidelines for Source BioScience's Automated
Cervical Cancer Screening Technology

Cervical Screening Wales are first in the UK to adopt the new technology

Source BioScience (LSE: SBS), the international diagnostics and genetic
analysis business, is pleased to announce that the National Health Service
Cancer Screening Programmes (`NHSCSP') has published its guidelines for the use
of the BD FocalPoint technology for cervical cancer screening in the UK.

Following the publication of the guidelines, Cervical Screening Wales (`CSW')
announced their commitment to implement the technology across Wales from 1
January 2012, the first screening service in the UK to introduce automated
imaging into the cervical cancer screening programme. The agreement to provide
the BD FocalPoint to CSW is worth up to GBP0.6 million to July 2015.

The BD FocalPoint is the only automated technology for cervical cancer
screening approved for use by the NHS and is able to analyse and identify up to
25% of screening samples that can be reported as "all clear", requiring no
manual examination. With over 3.6 million tests being undertaken across England
and Wales during 2009/10, this represents a significant reduction in laboratory
workload and the need for additional staffing and outsourcing. It will also
help laboratories achieve the mandatory 14 day screening deadline for patients
to receive their test results promised to patients under the Department of
Health's Cancer Reform Strategy.

Dr Nick Ash, CEO at Source BioScience, commented: "The publication of the
implementation guidelines enables us to facilitate the introduction of
automated imaging to the NHS standards across England and Wales. There has been
considerable interest in adopting the technology from a large number of NHS
Trusts looking to improve screening turnaround times even further and we're
delighted to announce that Cervical Screening Wales are the first screening
service to adopt the technology in the UK."

He added: "Source BioScience is now able to provide customers with a unique and
complete solution for cervical cancer screening from sample collection,
processing, imaging and diagnostic testing, including HPV testing."

Bryan Rose, Head of Programme for Cervical Screening Wales said: "We are
pleased to be the first service to formally adopt the BD FocalPoint system for
the application of "No Further Review" (`NFR') in the cervical screening
programme in Wales. CSW has run an independent assessment of the technology
which has led us to recognise for some time the benefits of using automated
imaging for cervical screening. Following recognition in the MAVERIC study of
its utility and the recent publication by the NHSCSP of specific guidelines for
the use of BD FocalPoint technology, which establishes best practice, we can
now confidently implement the technology into our screening programme. The
technology will assist our laboratories to improve turnaround times within our
defined standards and enhance the quality of service that we provide for women
in Wales."

Hilja Ibert, VP GM BD Diagnostic Systems Europe commented: "The implementation
of BD FocalPoint is a direct outcome of our focus on improving health outcomes
for patients by providing laboratories with solutions that improve quality,
inform medical decisions and enhance laboratory system productivity. We
continuously invest in developing innovative solutions and technologies that
will further support and enhance the cervical cancer screening programs. We are
proud of our long-standing partnership with Source BioScience in the UK, for
their expert support and distribution of these technologies and the rapid
implementation of BD FocalPoint NFR."

--ENDS--

RSI on viagra.

Another strong candle.

Interim Management Statement.

Half Yearly report

Financial highlights

* Revenue increased by 11% to £8.4 million (2011: £7.6 million)

* EBITDA of £1.3 million (2011: £0.5 million)

* Operating profit of £0.5 million (2011: loss of £0.2 million)

* Profit before tax of £0.4 million (2011: loss of £0.2 million)

* EPS of 0.20p basic (2011: loss of 0.09p basic)

* Cash balance of £1.8 million (31 December 2011: £1.1 million)

Operational highlights

* Developments in LifeSciences business delivering growth:

*
+ DNA sequencing has grown by 60% year on year, driven by our Overnight
Service

+ Phase III of GenomeCube®, our proprietary web-based search engine and
bioinformatics tool is underway; this is enabling globalisation of
product portfolio and the appointment of overseas franchise
distributors

I'm in as of this morning..good story developing here (imho)

A load of BUYS today and only 3 SELLS out of 37 trades




Trades

Show the last 25 50 100 250 500 1000 All trades - Showing all 37 trades since market opening.

Latest trades

Time Price Volume Value Bid Ask B/S
15:17:55 12p 82,811 £9,937 11.75p 12p Buy
15:07:18 11.9p 3,250 £387 11.75p 12p Buy
14:33:04 11.9p 21,299 £2,535 11.75p 12p Buy
14:20:37 11.9p 12,437 £1,480 11.75p 12p Buy
14:08:54 11.9p 15,000 £1,785 11.75p 12p Buy
13:44:24 11.9p 5,000 £595 11.75p 12p Buy
13:26:40 11.9p 840 £100 11.75p 12p Buy
12:44:26 11.9p 10,084 £1,200 11.75p 12p Buy
12:38:43 11.9p 4,000 £476 11.75p 12p Buy
12:25:14 11.9p 18,520 £2,204 11.75p 12p Buy
12:11:27 11.9p 8,286 £986 11.75p 12p Buy
11:57:29 11.9p 8,403 £1,000 11.75p 12p Buy
11:47:33 11.9p 25,000 £2,975 11.75p 12p Buy
11:45:35 11.8p 4,662 £550 11.75p 12p Sell
11:19:12 11.9p 750 £89 11.75p 12p Buy
11:16:16 11.9p 3,500 £416 11.75p 12p Buy
11:12:39 11.9p 3,000 £357 11.75p 12p Buy
11:08:47 11.92p 10,000 £1,192 11.75p 12p Buy
11:05:13 11.9p 15,000 £1,785 11.75p 12p Buy
11:04:12 11.9p 16,893 £2,010 11.75p 12p Buy
11:01:05 11.91p 5,000 £596 11.75p 12p Buy
11:00:19 11.91p 25,314 £3,015 11.75p 12p Buy
10:52:21 11.91p 15,153 £1,805 11.75p 12p Buy
10:49:54 11.91p 23,280 £2,773 11.75p 12p Buy
10:42:06 11.92p 20,000 £2,384 11.75p 12p Buy
10:28:01 11.97p 5,112 £612 11.75p 12p Buy
10:25:53 11.88p 25,000 £2,970 11.75p 12p Buy
9:57:11 11.91p 329 £39 11.75p 12p Buy
9:55:35 11.65p 95,587 £11,136 11.75p 12p Sell
9:09:16 11.87p 92,117 £10,934 11.5p 12p Buy
9:02:47 11.71p 2,022 £237 11.5p 12p Sell
9:00:14 11.92p 8,243 £983 11.5p 12p Buy
8:26:41 11.92p 2,000 £238 11.5p 12p Buy
8:12:48 11.92p 4,048 £483 11.5p 12p Buy
8:04:03 11.87p 8,424 £1,000 11.5p 12p Buy
8:01:12 11.87p 8,000 £950 11.5p 12p Buy
8:01:06 11.87p 3,118 £370 11.5p 12p Buy


Today's summary Bid 11.75p
Ask 12p
High 12p
Low 11.65p
Open 11.75p
Previous close 11.75p
Mid price 11.88p
Change +0.25p (2.128%)
Volume 611.5K



2 of those buys were mine at 11.91p ....onwards and upwards...not expecting a quick return so will be an LTH....liking the story!

topped up today

Final Results

Financial highlights

* Revenue increased by 8% to GBP16.4 million (2011: GBP15.2 million)

* Operating profit more than doubled to GBP1.2 million (2011: GBP0.5 million
adjusted*)

* Profit before tax of GBP1.0 million (2011: GBP0.4 million adjusted*)

* EBITDA increased by 43% to GBP2.7 million (2011: GBP1.9 million adjusted*)

* Profit after tax of GBP3.5 million (2011: loss of GBP2.8 million)

* EPS 1.70 pence (2011: loss per share 1.37 pence)

* Cash generated from operating activities of GBP3.3 million (2011: GBP0.6
million)

* Cash balance of GBP2.2 million (2011: GBP1.1 million) and net debt of GBP0.9
million (2011: GBP2.3 million)

Offer Update

SOURCE BIOSCIENCE PLC ("SOURCE BIOSCIENCE" OR THE "COMPANY")
RECOMMENDED CASH OFFER FOR VINDON HEALTHCARE PLC ("VINDON")

OFFER DECLARED UNCONDITIONAL IN ALL RESPECTS



Source BioScience plc (LSE: SBS) the international diagnostics and genetic analysis services business, announces that its circa GBP 12.2 million recommended cash offer for Vindon Healthcare plc is now declared unconditional in all respects.

Highlights

· On 13 September 2013, Source BioScience announced that it had received valid acceptances in respect of more than 90 per cent. of the entire issued share capital of Vindon and the Offer had become unconditional as to acceptances
· The acquisition is part funded by the Firm Placing which raised GBP 9.5 million (gross) from existing and new institutional investors and a new banking facility
· Following the admission to trading of the Firm Placing Shares at 8.00 a.m. on 13 September 2013 and the conclusion of other completion matters, the Offer is now unconditional in all respects
· The Offer will remain open for acceptances until further notice. At least 14 days' notice will be given before Source BioScience closes the Offer to further acceptances. In accordance with the Companies Act, compulsory acquisition measures may be used to acquire Vindon Shares not assented to the Offer
· Vindon Shareholders who have not yet accepted the Offer are reminded to do so as soon as possible. Details of the procedure for doing so are set forth in the Offer Document (including, in the case of certificated Vindon Shares, the Form of Acceptance) sent to Vindon Shareholders on 7 August 2013
· The residual net proceeds of the Firm Placing (after partial funding of the consideration for the Offer and related expenses) will be used, together with the circa GBP 0.8 net proceeds of the recently completed million Open Offer, to fund additional organic and selected acquisitive growth initiatives for the enlarged Source BioScience Group

The Offer will remain open for acceptances until further notice. At least 14 days' notice will be given before Source BioScience closes the Offer to further acceptances. Vindon Shareholders who have not yet accepted the Offer are reminded to do so as soon as possible. Details of the procedure for doing so are set forth in the Offer Document (including, in the case of certificated Vindon Shares, the Form of Acceptance) sent to Vindon Shareholders on 7 August 2013.

Source Bioscience - was Medical Solutions....DYOR.
This has been a sorry-state investment . . . so at last the fools (like me!), that believed Execs words have their hopes finalised.
Well, apart from anyone that bought recently, this has been dire - and the Sept 2016 OFFER at least provides a decent EXIT.....at a paper loss....but then, the money was lost to any better "Good Use" from early days - as they tried to maintain interest, etc.


The lack of Posts since Sept. 2013 indicates how little excitement there has been in this dire business.